Encompass Health Corporation $EHC Shares Bought by Ancora Advisors LLC

Key Points

• Ancora Advisors increased its Encompass Health stake by 13.7% in the second quarter, bringing its holdings to 105,258 shares valued at approximately $10.6 million. Institutional investors own 97.25% of the company.
• Encompass Health reported quarterly earnings of $1.55 per share, beating estimates of $1.48, while revenue rose 9.6% year over year to $1.60 billion. The company issued fiscal 2026 EPS guidance of $6.02–$6.25.
• The company raised its quarterly dividend from $0.19 to $0.21 per share, while insiders sold roughly $23.4 million of stock over the past 90 days. Analysts maintain a consensus “Buy” rating with an average price target of $148.71.

Ancora Advisors LLC grew its stake in Encompass Health Corporation (NYSE:EHC - Free Report) by 13.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 105,258 shares of the company's stock after purchasing an additional 12,720 shares during the period. Ancora Advisors LLC owned about 0.11% of Encompass Health worth $10,639,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in EHC. Transamerica Financial Advisors LLC purchased a new position in Encompass Health in the second quarter valued at $29,000. Persistent Asset Partners Ltd purchased a new stake in shares of Encompass Health during the 2nd quarter worth about $36,000. Keating Financial Advisory Services Inc. acquired a new stake in shares of Encompass Health during the 2nd quarter valued at about $39,000. Assetmark Inc. grew its position in shares of Encompass Health by 89.6% during the 1st quarter. Assetmark Inc. now owns 455 shares of the company's stock valued at $44,000 after acquiring an additional 215 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Encompass Health by 36,200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company's stock valued at $46,000 after purchasing an additional 362 shares in the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Encompass Health

In other Encompass Health news, EVP John Patrick Darby sold 8,906 shares of Encompass Health stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.95, for a total transaction of $1,121,710.70. Following the transaction, the executive vice president directly owned 75,041 shares of the company's stock, valued at $9,451,413.95. The trade was a 10.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mark J. Tarr sold 173,148 shares of the business's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the completion of the transaction, the chief executive officer owned 267,814 shares in the company, valued at $33,602,622.58. The trade was a 39.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 186,912 shares of company stock worth $23,434,845 over the last ninety days. 1.80% of the stock is owned by insiders.

Encompass Health Price Performance

EHC stock opened at $122.23 on Wednesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.19 and a quick ratio of 1.19. The business has a 50 day simple moving average of $114.08 and a 200-day simple moving average of $107.33. The firm has a market capitalization of $12.06 billion, a PE ratio of 19.91, a price-to-earnings-growth ratio of 2.43 and a beta of 0.74. Encompass Health Corporation has a 1 year low of $92.77 and a 1 year high of $127.99.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, topping analysts' consensus estimates of $1.48 by $0.07. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.57 billion. Encompass Health had a return on equity of 18.08% and a net margin of 10.01%.The firm's revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 earnings per share. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Equities research analysts anticipate that Encompass Health Corporation will post 6.08 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be given a dividend of $0.21 per share. The ex-dividend date is Thursday, October 1st. This is an increase from Encompass Health's previous quarterly dividend of $0.19. This represents a $0.84 annualized dividend and a yield of 0.7%. Encompass Health's dividend payout ratio (DPR) is 12.38%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on EHC shares. Wall Street Zen raised Encompass Health from a "hold" rating to a "buy" rating in a research note on Sunday, August 16th. Weiss Ratings raised shares of Encompass Health from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 12th. Barclays lifted their target price on shares of Encompass Health from $140.00 to $144.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. UBS Group upped their price target on shares of Encompass Health from $150.00 to $155.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, TD Cowen raised their price target on shares of Encompass Health from $125.00 to $140.00 and gave the company a "buy" rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Encompass Health presently has an average rating of "Buy" and an average price target of $148.71.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source